Results for tag: "Hepcidin Antagonist"

The Hepcidin Antagonist market is a subset of the Hematological Drugs market, which focuses on treatments for blood-related diseases. Hepcidin Antagonists are drugs that target the hepcidin protein, which is responsible for regulating iron levels in the body. By blocking the hepcidin protein, these drugs can help to increase iron levels in patients with anemia, a condition characterized by low iron levels. These drugs are used to treat a variety of hematological diseases, including anemia, thalassemia, and sickle cell disease. The Hepcidin Antagonist market is a relatively new and emerging field, with several companies developing drugs to target the hepcidin protein. Companies such as Akebia Therapeutics, FibroGen, and Arbutus Biopharma are actively researching and developing drugs to target hepcidin. Additionally, several pharmaceutical companies, such as Novartis and Pfizer, are also investing in the development of hepcidin antagonists. Show Less Read more